Tashjian A.H., Hohmann E.L., Antonaides H.N.
è ñîàâò. Platelet derived growth
factor stimulates bone resorption via a prostaglandin mediated mechanism //
Endocrinology. — 1982. — V. 111. — P. 118 124.
Tashjian A.H., Voelkel E.F., Lazzaro M.
è ñîàâò. ( and ( transforming growth factors
stimulate prostaglandin production and bone resorption in cultured mouse calvaria //
Proc. Natl. Acad. Sci. USA. — 1985. — V. 82. — P. 4535 4538.
Tashjian A.H., Voelkel E.F., Lloyd W., Derynck R., Winkler M.E., Levine I.
Actions
of growth factors on plasma calcium: epidermal growth factor and transforming growth
factor alpha cause elevation of plasma calcium in mice // J. Clin. Invest. — 1986. — V. 78.
— P. 1405 1409.
Tashjian A.H., Voelkel E.F., Lazzaro M.
è ñîàâò. Tumor necrosis factor
((cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin mediated
mechanism // Endocrinology. — 1987. — V. 120. — P. 2029 2036.
Tateishi A.
Diagnosis and treatment of metastatic bone cancer // Gan To Kagaku
Ryoho 1996. — V. 23(10). — P. 1262 1268.
Tateishi A., Higaki S., Abe S., Nakano H.
Treatment of pathological fractures caused
by metastatic bone cancer // Gan To Kagaku Ryoho. — 1997. — V. 24(3). — P. 285 291.
Tatsui H., Onomura T., Morishita S., Oketa M., Inoue T.
Survival rates of patients
with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accu
mulation // Spine. — 1996. — V. 21(18). — P. 2143 2148.
Taube T., Elomaa I., Blomqvist C., Beneton M.N., Kanis J.A.
Histomorphometric
evidence for osteoclast mediated bone resorption in metastatic breast cancer // Bone. —
1994. — V. 15(2). — P. 161 166.
Taylor S.G.
4th
, Gelman R.S., Falkson G.,
è ñîàâò. Combination chemotherapy com
pared to tamoxifen as initial therapy for stage IV breast cancer in elderly women // Ann.
Intern. Med
. —
1986. — V. 104. — P. 455 461.
Theissen P., Smolarz K., Scharl A., Groth A., Scheidhauer K., Voth E., Schicha H.
Magnetic resonance imaging in screening for bone metastasis? A prospective comparison
with bone scintigraphy // Nuklearmedizin. — 1994. — V. 33(4). — P. 132 137.
Theriault R.L., Lipton A., Leff R.,
è ñîàâò. Reduction of skeletal related complica
tions in breast cancer patients with osteolytic bone metastases receiving hormone therapy,
by monthly pamidronate sodium (Aredia) infusion // Proc. Am. Soc. Clin. Oncol. — 1996.
— V. 15. — P. 122 (A 152).
Theriault R.L., Lipton A., Hortobagyi G.N.
è ñîàâò. Pamidronate reduces skeletal
morbidity in women with advanced breast cancer and lytic bone lesions: a randomized,
placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group // J. Clin. Oncol.
— 1999. — V. 17. — P. 846 854.
Thiebaud D., Jaeger J., Jacquet A.F.,
è ñîàâò. Dose response in the treatment of
hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrPB // J.
Clin. Oncol. — 1988. — V. 6. — P. 762 768.
Thomas P.
Radiotherapy of metastases of mammary carcinoma // Radiol. Clin. —
1976. — V. 45. — P. 306 313.
Thurlimann B., Castiglione M., Hsu+Schmitz S.F.,
è ñîàâò. Formestane versus mege
strol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III
prospective randomised cross over trial of second line hormonal treatment (SAKK 20/90).
Swiss Group for Clinical Cancer Research (SAKK) // Eur. J. Cancer. –1997. — V. 33. —
P. 1017 1024.
250
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
